MAR001

Sirius Therapeutics has completed a nearly $50 million Series B2 financing round led by a corporate venture capital firm, with participation from new investor BioTrack Capital and existing investors.

Marea Therapeutics' monoclonal antibody MAR-001 demonstrated significant reductions in remnant cholesterol (up to 52.5%) and triglycerides (up to 52.7%) in Phase 2a cardiovascular disease trial.

Versant Ventures has launched Granite Bio with $100 million in funding, advancing two novel antibody drugs targeting inflammatory conditions through its Ridgeline Therapeutics initiative.

Researchers from Imperial College London and Lund University found that early combination therapy with statins and ezetimibe significantly reduces the risk of subsequent heart attacks and death in cardiac patients.

Marea Therapeutics' MAR001 demonstrated clinically significant reductions in remnant cholesterol and triglycerides in a Phase 2a trial for cardiovascular disease.